

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

School readiness among children born to women living with HIV in Dar es Salaam, Tanzania: a cohort study protocol

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001572
Article Type:	Protocol
Date Submitted by the Author:	08-Jun-2022
Complete List of Authors:	Perumal, Nandita; Harvard University T H Chan School of Public Health, Department of Global Health and Population Saleh, Arvin; Harvard University T H Chan School of Public Health, Department of Global Health and Population Muhihi, Alfa; Muhimbili University of Health and Allied Sciences, Department of Community Health; Management and Development for Health Seiden, Jonathan; Harvard Graduate School of Education Ndesangia, Veneranda; Muhimbili University of Health and Allied Sciences, Department of Pediatrics Ulenga, Nzovu; Management and Development for Health McCoy, Dana ; Harvard Graduate School of Education Bakari, Mohamed; Muhimbili University of Health and Allied Sciences, Department of Pediatrics Sudfeld, Christopher; Harvard University T H Chan School of Public Health, Department of Global Health and Population Manji, Karim; Muhimbili University of Health and Allied Sciences, Department of Pediatrics
Keywords:	HIV, Epidemiology, Growth

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

School readiness among children born to women living with HIV in Dar es Salaam, Tanzania: a cohort study protocol

Nandita Perumal¹, Arvin Saleh¹, Alfa Muhihi^{2,3}, Dana McCoy⁴, Jonathan Seiden⁴, Mohamed Bakari⁵, Veneranda Ndesangia⁵, Nzovu Ulenga², Christopher R. Sudfeld^{1,6*}, Karim P. Manji^{5*}

*co-senior authors

¹ Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, United States

² Management and Development for Health, Dar es Salaam, Tanzania

³ Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

⁴ Harvard Graduate School of Education, Harvard University, Boston, United States

⁵ Department of Pediatrics, Muhimbili University Health and Allied Sciences, Tanzania

⁶ Department of Nutrition, Harvard TH Chan School of Public Health, Boston, United States

Corresponding Author

Nandita Perumal, PhD MPH

Department of Global Health and Population

Harvard TH Chan School of Public Health

90 Smith Street, 3rd Floor

Boston USA 02215

Email: nperumal@hsph.harvard.edu

Word count: 2550

Abstract

Introduction: Children who are born to women living with HIV are at a greater risk of suboptimal neurodevelopment; however, evidence from sub-Saharan Africa is limited and functional developmental outcomes are rarely assessed in this vulnerable population. The School Readiness among HIV-Exposed Children (SRHEC) cohort study aims to assess the school readiness of pre-school aged children born to women living with HIV and to identify the biological, environmental, and social factors that contribute to school readiness in this population.

Methods and analysis: The SRHEC cohort is an observational follow-up study of children born to HIV-infected pregnant women who were previously enrolled in a maternal vitamin D supplementation randomized, placebo-controlled trial in Dar es Salaam, Tanzania. This parent trial enrolled 2,300 pregnant women and followed mothers and infants up to one year postpartum. Mother/caregiver and child pairs will be eligible for the SRHEC follow-up study if the child is between 3-6.5 years of age at assessment, and the mother/caregiver provides informed consent. The International Development and Early Learning Assessment (IDELA) tool will be used to assess children's school readiness, including their early literacy, early numeracy, motor, social-emotional, and executive function skills. Data on maternal and child health and nutritional status (e.g., anthropometry, blood pressure, and diet) will be collected using standardized instruments and survey-based questionnaires. Data on maternal/caregiver depression and anxiety, maternal exposure to intimate partner violence, and HIV-related stigma will also be collected. Generalized linear and logistic regressions will be used to assess the relationship between child school readiness and biological, social, environmental factors.

Ethics and Dissemination: This study received ethical clearance from the Tanzanian National Institute of Medical Research, the Muhimbili University Health and Allied Sciences, and the Harvard T.H. Chan School of Public Health. We will disseminate our results in the form of scientific conference presentations and peer-reviewed publications.

What is already known on this topic

- With increasing availability of antiretroviral therapy for HIV-infected pregnant women in low-resource settings, the number of children who are HIV-exposed but uninfected (HEU) is increasing.
- HEU children are at a greater risk of suboptimal growth and development; however, evidence to date has been primarily from high-income settings.
- Furthermore, functional developmental outcomes, such as school readiness, are rarely assessed in HIV-affected pediatric populations.

What this study hopes to add

- This prospective cohort study aims to assess the school readiness of pre-school aged children born to women living with HIV in Dar es Salaam, Tanzania.
- The study also aims to identify the biological, environmental, and social factors that contribute to school readiness in this population.
- Study findings will provide robust data for designing interventions to support school readiness and ensure optimal growth and development outcomes among HIV-affected children.

Introduction

In 2015, the World Health Organization (WHO) released guidelines, known colloquially as “Option B+”, which recommended that all pregnant and breastfeeding women with human immunodeficiency virus (HIV) should initiate lifelong antiretroviral therapy (ART), regardless of HIV disease stage, to prevent mother-to-child transmission and sexual transmission of HIV, and to improve maternal clinical outcomes.¹ With global efforts continuing to increase the availability of and access to ART for women living with HIV in low-resource settings, the number of children who are HIV exposed, but uninfected (HEU) is increasing. Globally, 14.8 million children aged 0 to 14 years are estimated to be HEU, 13.2 million of whom reside in sub-Saharan Africa.² The number of HEU children has increased between 100% to ~800% in the highest burden countries in sub-Saharan Africa since 2000.³

Evidence primarily from in high-income settings suggests that children who are born to women living with HIV are at a greater risk for suboptimal cognitive, motor, behavioral, and socioemotional development as compared to their HIV-unexposed peers.⁴⁻⁶ Biological risk factors, such as exposure to HIV and ART in-utero, increased risk of maternal illness, poor nutrition during pregnancy, and increased risk of being born low birthweight or preterm have been associated with higher risk of poor development among young children.^{7,8} Numerous social, economic, and environmental factors related to living in an HIV-affected household, such as parental mental health and depression, stigma, reduced parental attention, and reduced availability of resources and income are also likely to influence children’s development.^{4,5} However, the relative contribution of the biological and social, socioeconomic and environmental risk factors on the risk of suboptimal developmental outcomes of HIV-affected children in the context of sub-Saharan Africa remains unclear. In addition, few studies have examined the functional outcomes related to early development, such as school readiness, which comprises of a range of both academic and non-academic early learning and developmental skills that support successful engagement in schools, among HIV-affected children.

1
2
3 The Sustainable Development Goal (SDG) Target 4.2 calls for all girls and boys to have access to quality
4 early childhood development, care, and pre-primary education to ensure that they are ready for primary
5 education.⁹ Given the known developmental inequities faced by young HIV-affected children, there is an
6 urgent need to understand what factors influence school readiness among HIV-affected children and to
7 develop and implement interventions to support school readiness in this vulnerable population. To this
8 end, the School Readiness among HIV-Exposed Children (SRHEC) cohort study aims to assess the
9 development and school readiness of pre-school aged children born to women living with HIV in Dar es
10 Salaam, Tanzania, and to identify the biological, social, and environmental risk and protective factors that
11 contribute to the school readiness in this population. The findings from this study will provide a unique
12 opportunity to disentangle the multi-faceted relationships that influence child school readiness in HIV-
13 affected pediatric populations, and to identify points of intervention to support child development.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Methods**

29 **Parent trial and cohort study design**

30
31 The SRHEC cohort study is a cross-sectional follow-up of children born in an individually randomized
32 double-blind, placebo-controlled trial of maternal vitamin D₃ (cholecalciferol) supplementation conducted
33 among pregnant women living with HIV in Dar es Salaam, Tanzania (ClinicalTrials.gov: NCT02305927).
34
35 The detailed protocol of the trial, which was conducted between 2015-2019, has been published
36 elsewhere.^{10,11} Briefly, the parent trial enrolled 2300 pregnant women living with HIV, who were ≥ 18
37 years of age, in the second trimester of pregnancy (12 – 27 weeks gestational age), and receiving ART, to
38 investigate whether daily vitamin D supplementation (3000 IU/day) could provide a low-cost adjunct
39 intervention to improve maternal and child health outcomes. Pregnant women were enrolled in the trial
40 from five public antenatal care clinics that provided antenatal care for pregnant women living with HIV.
41
42 During the trial, Tanzania used the Option B+ approach, where all pregnant women living with HIV were
43 initiated on lifelong triple-drug ART, irrespective of CD4 T-cell counts or HIV disease stage. The first
44 line of ART during the trial was tenofovir/lamivudine/efavirenz, which was used by 99% of women in the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 trial during pregnancy and the first year postpartum. Participants were followed at monthly visits during
4 the prenatal period, at delivery, at 6, 10, and 14 weeks postpartum, and monthly thereafter up to 12
5 months postpartum. Detailed information on maternal sociodemographic characteristics, clinical
6 outcomes (including HIV disease stage), nutrition status, and depressive symptoms were collected during
7 the prenatal period. In the postpartum period, mothers' follow-up assessments included clinical
8 examination, HIV disease stage assessment, and anthropometric measurement. Child follow-up
9 assessments included detailed clinical examination, infant feeding practices, and anthropometry, as well
10 as child development at the last visit. The primary outcomes of the trial were maternal HIV progression or
11 death from any cause, small-for-gestational age (SGA) births, and infant stunting (length-for-age z-score
12 <-2 standard deviation from the median of the reference population) at 12 months of age. Vitamin D
13 supplementation had no effect on the primary trial outcomes.¹¹
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Participant eligibility for follow up**

29
30 All mother-child pairs who previously participated in the trial of maternal vitamin D supplementation will
31 be eligible for inclusion in the SRHEC follow-up study if: (i) child age is between 3 to 6.5 years at the
32 time of assessment, and (ii) the mother/caregiver provides informed consent. For a child whose mother
33 was enrolled in the trial of vitamin D supplementation but was not available for the follow-up study (e.g.,
34 due to death), we will ask the child's current primary caregiver for consent to participate. We will use
35 information collected during the parent trial to invite women previously enrolled in the parent trial for the
36 follow-up study. Mother/caregiver and child pairs will be invited to the study clinics to learn more about
37 the follow-up study and for study assessments if they agree to participate. Women who previously
38 withdrew from the parent trial or who were lost to follow-up during the trial period, which was until 1-
39 year postpartum, will not be contacted. Written informed consent will be obtained from all participants in
40 Kiswahili.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study procedures and assessments

Eligible mother/caregiver and child pairs who consent to participate in the follow-up study will be assessed in quiet rooms at study clinics in tertiary hospitals in Dar es Salaam, Tanzania. For each mother/caregiver and child pair we will collect detailed information on various domains, including sociodemographic factors, nutritional status, mental health status, and child development and school readiness (Table 1). Tools and procedures used to measure each of these domains are described below.

Table 1: Types of assessment planned for mother/caregiver and child pairs.

Assessment components	Mother/Caregiver*	Child
Sociodemographic characteristics	x	
Health and nutritional status	x	x
Parenting practices	x	
Mental health	x	
Social support	x	
Intimate partner violence	x	
HIV-stigma	x	
Early learning and development		
International Development and Early Learning Assessment		x
Early Child Development Index 2030		x
Strengths and Difficulties questionnaire		x

*Caregiver assessments will not include the health and nutritional status and the intimate partner violence and HIV-stigma components.

(i) Child development and school readiness: We will use the International Development and Early Learning Assessment (IDELA) tool developed by Save the Children to assess school readiness in young children aged 3 to 6.5 years in low-resource settings.¹² Briefly, the IDELA is a tool with 22 subtasks that is easily-administered, holistic, rigorous, culturally adaptable and open-source, used to assess four core domains: (1) motor development, (2) emergent literacy, (3) emergent numeracy, (4) social-emotional development, plus an optional module on (5) executive functioning (i.e., short-term memory, inhibitory control, sustained attention). The IDELA is designed to capture broadly cross-culturally relevant skills

1
2
3 that support children's transition into formal learning environments in school. It is administered on a one-
4 on-one basis, does not require specific disciplinary trainings, and is administered using a minimal set of
5 materials: a pencil, blank paper, small items for counting (such as beans or buttons), nine picture cards,
6 and a storybook. The IDELA tool has been previously adapted for and used in Tanzania.¹³ We will assess
7 inter-rater reliability for 5% of IDELA assessments selected at random.
8
9
10
11
12

13
14
15 As a secondary measure of development, we will implement the Early Child Development Index 2030
16 (ECDI2030), which is commonly used in population-based surveys to assess whether a child is meeting
17 expected developmental milestones in motor, language, math, literacy, executive functioning, and socio-
18 emotional domains.¹⁴ The ECDI2030 is used to evaluate progress towards SDG target 4.2 and is
19 administered as 20 close-ended questions to the mother or primary caregiver, where they indicate whether
20 their child has exhibited behaviors in each question. We will also use the Strengths and Difficulties
21 Questionnaire (SDQ), which has previously been implemented in Tanzania, to assess children's overall
22 mental health status as indexed by internalizing and externalizing behaviors.¹⁵ Like the ECDI2030, the
23 SDQ is a mother/caregiver-reported instrument; it includes 25 items rated on a Likert-like scale assessing
24 frequency of behavior.¹⁶ All child development and school readiness tools will be administered by nurses,
25 who will be trained using the standard training procedures for each tool.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **(ii) Maternal and child health and nutrition:** We will use standardized procedures to measure
42 anthropometry. Maternal and child weight will be measured using electronic floor scale (ADE M320600,
43 Germany) with 50 g precision up to 50 kg, and 100 g precision thereafter. Participants will be requested to
44 remove shoes and wear light clothing at the time of weight measurement. Maternal and child standing
45 height will be measured using a stadiometer (ADE Mechanical Height MZ10017, Germany) with 1mm
46 precision and mid-upper arm circumference (MUAC) will be measured using a circumference tap
47 measure (ADE MZ10021, Germany) with 1mm precision. Child head circumference will be measured
48 using a Schorr tape with 1 mm precision. All child anthropometric measures will be taken in triplicate and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 maternal measures will be recorded in duplicate. In addition to anthropometry, we will measure maternal
4 blood pressure in duplicate, using a digital blood pressure machine (OMRON BP7200) with free-size
5 cuff, with participant in a seated position after five minutes of rest. Anthropometric equipment will be
6 calibrated daily, and the blood pressure monitor will be calibrated every month using a manual mercury
7 sphygmomanometer. Minimum dietary diversity for women of reproductive age (MDD-W) will be
8 assessed using the Food and Agriculture Organization guidelines.¹⁷ Child diet will be assessed using a
9 modified 24-hour recall for infant and young child feeding practices (removing any items relevant to
10 children <2 years of age only) where mothers/caregivers are asked about the types of foods consumed by
11 the child in the last 24 hours to record the food groups.¹⁸ We will also assess child's current health status
12 as measured by episodes of morbidity, such as diarrhea and fever, in the two-week period prior to the
13 assessment.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **(iii) Maternal/Caregiver mental health and social support:** Maternal depression will be assessed using
30 the Hopkins Symptom Checklist (HSCL-25), which is comprised of 15 items on depressive symptoms
31 and 10 items on anxiousness symptoms; it has previously been validated for use in Tanzania among
32 pregnant women living with HIV.¹⁹ We will also measure the mother's perception of social support using
33 an adapted Duke University–University of North Carolina Functional Social Support Questionnaire,
34 consisting of 8 questions to measure constructs of support from confidants and affective support.²⁰ The
35 tool has been previously adapted for use in Tanzania and can be used to distinguish between two
36 underlying constructs of instrumental and emotional support.²¹ We will also measure depression and
37 perception of social support for primary caregivers, should the mother be unavailable.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **(iv) Maternal HIV-related stigma and intimate partner violence (IPV):** We will measure mothers'
52 reports of HIV-related stigma using an abbreviated version the Berger scale,²² which has been previously
53 used in Tanzania,^{23,24} and consists of 7 questions to capture internalized stigma (shame, guilt) and
54
55
56
57
58
59
60

externalized stigma as experienced by treatment from other people who are aware of the respondent's HIV status. We will also assess prevalence of IPV, which in this context is most commonly directed towards women by male partners. IPV has been described to manifest in a range of behaviors, including but not limited to: physical, sexual, emotional or psychological, and controlling behaviors that include restricting financial or economic independence.²⁵ Physical and sexual aspects of IPV will be assessed using an abbreviated mother-reported IPV module found in the Tanzania Demographic and Health Survey and has been previously used in other studies.^{26,27} Emotional and economic aspects of IPV will be assessed using abbreviated questions that were previously used in Tanzania.²⁸ We will not assess HIV-related stigma or IPV for caregivers.

(v) Caregiving practices and resources for learning: Caregiving practices, including disciplinary practices, such as corporal punishment, and responsive caregiving and stimulation practices (e.g., reading, counting, playing), will be measured using the mother/caregiver-reported Family Care Indicators taken from the Multiple Indicator Cluster Surveys.^{29,30} We will also collect data on resources available for learning, such as books and toys, to assess children's learning environment at home, using items from the Family Care Indicators.

(vi) Maternal HIV variables at time of assessment: We will seek consent to retrieve mother's medical information from the HIV treatment clinic and to link HIV treatment information, including information on HIV disease stage based on the WHO classification, history of ART regimens, viral load and laboratory results.

(vii) Data collected during pregnancy and first year postpartum: We will link the maternal/caregiver and child data collected in this study with existing data from parent vitamin D supplementation trial to assess long-term associations of maternal and child perinatal health with child development and school readiness in the pre-school years.

Safety procedures and referrals

All research staff will be trained in a 2-week training workshop where they will learn about and familiarize themselves with all study procedures, including the planned referral scheme and supports that will be made available to participants and their children. Study staff members will also be trained in referring study mothers/caregivers for mental health care if they report IPV or depression. If signs of suicidality are reported, mothers/caregivers will be kept under observation until they are seen by a clinical psychiatrist and referred for mental health services. Mothers/caregivers and their children will be referred to clinical and nutritional services at the hospital if undernutrition and malnutrition are detected. We will follow strict safety precautions and procedures (e.g., masks, hand sanitizers) to prevent the transmission of COVID-19 among the study staff and participants.

Sample size

All mother and infant pairs who were discharged from the parent trial at 12 months postpartum (n = 2053) will be eligible for the SRHEC follow-up study and will be invited to participate in the study.

Quality assurance and data management

Standardization sessions will be held every 3 months to ensure the data collectors are following the recommended techniques, to monitor reliability (precision and accuracy), and to take corrective measures if required. Data queries will be regularly generated and checked by study field staff as part of quality assurance/quality control measures to detect outliers and possible erroneous values.

Statistical analysis

We will generate summary statistics, including means and proportions, of child outcome domains as described in the standard methodology for the IDELA, ECDI2030, and SDQ measures including both domain-level and overall scores where appropriate. Subscale scores for caregiving practices, resources for

1
2
3 learning, maternal depression, and anxiety, will be similarly derived using internationally validated
4 standards and cutoffs when available, and sum scores or z-scores as relevant. Child growth will be
5 assessed using standardized indices and indicators of anthropometric measures using the World Health
6 Organization Child Growth Standards.^{31,32} Scores for child development and school readiness will be
7 converted to z-scores based on study sample distribution with a mean of 0 and an SD of 1 for analysis.
8 We will estimate differences in child health, nutrition, development and school readiness outcome scores
9 across different exposures of interest using generalized linear regression models. Relationships with
10 categorical indicators of suboptimal child development will be estimated using modified Poisson
11 regression with robust standard errors. All regression models will be adjusted for potential
12 sociodemographic confounders, such as child age, child sex, maternal/caregiver age, household wealth
13 quintile, and number of children in the household, among others.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Ethics and dissemination**

29
30 This study received ethical clearance from the Tanzanian National Institute of Medical Research, the
31 Muhimbili University Health and Allied Sciences, and the Harvard TH Chan School of Public Health.
32 Permission to conduct the study was granted by the President's Office, Regional Administration and
33 Local Government (PORALG) and the Regional Medical Officer (RMO) of Dar-es-Salaam. We will
34 disseminate our results in the form of scientific conference presentations, presentations to the RMO, and
35 as peer-reviewed publications.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 World Health Organization. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. *Geneva WHO* 2012: 1–117.
- 2 Slogrove A, Reikie B, Naidoo S, *et al.* HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. *J Trop Pediatr* 2012; 58: 505–8.
- 3 Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global population of children who are HIV-exposed and uninfected, 2000–18: a modelling study. *Lancet Glob Heal* 2020; 8: e67–75.
- 4 Sherr L, Croome N, Parra Castaneda K, Bradshaw K, Herrero Romero R. Developmental challenges in HIV infected children-An updated systematic review. *Child Youth Serv Rev* 2014; 45: 74–89.
- 5 Le Doaré K, Bland R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. *Pediatrics* 2012; 130.
- 6 Stein A, Desmond C, Garbarino J, *et al.* Predicting long-term outcomes for children affected by HIV and AIDS: Perspectives from the scientific study of children’s development. *AIDS* 2014; 28: 261–8.
- 7 Chen JY, Ribaud HJ, Souda S, *et al.* Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in botswana. *J Infect Dis* 2012; 206: 1695–705.
- 8 Moran NF, Moodley J. The effect of HIV infection on maternal health and mortality. *Int J Gynecol Obstet* 2012; 119: 26–9.
- 9 UNICEF. The sustainable development goals. 2015.
- 10 Sudfeld CR, Manji KP, Duggan CP, *et al.* Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: Study protocol for a randomized controlled trial. *Trials* 2017; 18: 1–12.
- 11 Sudfeld CR, Manji KP, Muhihi A, *et al.* Vitamin D3 supplementation during pregnancy and lactation for women living with HIV in Tanzania: A randomized controlled trial. *PLoS Med* 2022; 19: e1003973.
- 12 Pisani L, Borisova I, Dowd AJ. Developing and validating the International Development and Early Learning Assessment (IDELA). *Int J Educ Res* 2018; 91: 1–15.
- 13 EQUIP-T. Review of the EQUIP-Tanzania School Readiness Programme. 2016; : 1–36.
- 14 Cappa C, Petrowski N, De Castro EF, *et al.* Identifying and minimizing errors in the measurement of early childhood development: Lessons learned from the cognitive testing of the ECDI2030. *Int J Environ Res Public Health* 2021; 18.
- 15 Winje BA, Kvestad I, Krishnamachari S, *et al.* Does early vitamin B₁₂ supplementation improve neurodevelopment and cognitive function in childhood and into school age: a study protocol for extended follow-ups from randomised controlled trials in India and Tanzania. *BMJ Open* 2018; 8: e018962.
- 16 Hoosen N, Davids EL, de Vries PJ, Shung-King M. The Strengths and Difficulties Questionnaire (SDQ) in Africa: A scoping review of its application and validation [Child Adolesc Psychiatry Ment Health., 12, (2018) (6)] DOI: 10.1186/s1303401702121. *Child Adolesc Psychiatry Ment Health* 2018; 12: 1–39.

- 1
2
3 17 FAO & FHI 360. Minimum Dietary Diversity for Women- A Guide to Measurement. 2016
4 www.fao.org/publications%0Ahttps://www.sciencedirect.com/science/article/abs/pii/S030691921
5 7301902.
6
7 18 WHO and UNICEF. Indicators for assessing infant and young child feeding practices. *World Heal*
8 *Organ United Nations Child Fund* 2021; WHA55 A55/: 19.
9
10 19 Kaaya SF, Fawzi MCS, Mbwapo JK, Lee B, Msamanga GI, Fawzi W. Validity of the Hopkins
11 Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania. *Acta Psychiatr Scand*
12 2002; 106: 9–19.
13
14 20 Broadhead_The Duke-UNC Functional Social Support Questionnaire.pdf. .
15
16 21 Regan M, Muhihi A, Nagu T, *et al.* Depression and Viral Suppression Among Adults Living with
17 HIV in Tanzania. *AIDS Behav* 2021; 25: 3097–105.
18
19 22 Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric
20 assessment of the HIV stigma scale. *Res Nurs Heal* 2001; 24: 518–29.
21
22 23 Smith Fawzi MC, Siril H, Larson E, *et al.* Healthy Options: Study protocol and baseline
23 characteristics for a cluster randomized controlled trial of group psychotherapy for perinatal
24 women living with HIV and depression in Tanzania. *BMC Public Health* 2020; 20: 1–10.
25
26 24 Fawzi MCS, Siril H, Liu Y, *et al.* Agents of change among people living with HIV and their social
27 networks: Stepped-wedge randomised controlled trial of the NAMWEZA intervention in Dar es
28 Salaam, Tanzania. *BMJ Glob Heal* 2019; 4: 1–14.
29
30 25 Krishnan N, Bewsley S. Domestic abuse. In: Dalton M, ed. *Forensic Gynaecology (Royal College*
31 *of Obstetricians and Gynaecologists Advanced Skills*. Cambridge: Cambridge University Press,
32 2014: 148–62.
33
34 26 Neamah HH, Sudfeld C, McCoy DC, *et al.* Intimate partner violence, depression, and child growth
35 and development. *Pediatrics* 2018; 142.
36
37 27 TDHS. Tanzania 2015-16 Demographic Health Survey and Malaria Indicator Survey. *Tanzania*
38 *2015-16 Demogr Heal Surv Malar Indic Surv* 2016; : 24.
39
40 28 Harvey S, Lees S, Mshana G, *et al.* A cluster randomized controlled trial to assess the impact on
41 intimate partner violence of a 10-session participatory gender training curriculum delivered to
42 women taking part in a group-based microfinance loan scheme in Tanzania (MAISHA CRT01):
43 Study pro. *BMC Womens Health* 2018; 18: 1–12.
44
45 29 Hamadani JD, Tofail F, Hilaly A, Huda SN, Engle P, Grantham-McGregor SM. Use of family care
46 indicators and their relationship with child development in Bangladesh. *J Heal Popul Nutr* 2010;
47 28: 23–33.
48
49 30 Kariger P, Frongillo EA, Engle P, Britto PMR, Sywulka SM, Menon P. Indicators of family care
50 for development for use in multicountry surveys. *J Heal Popul Nutr* 2012; 30: 472–86.
51
52 31 WHO Multicentre Growth Reference SG. WHO Child Growth Standards based on Legnth/height,
53 weight and age. *Acta Paediatr (Oslo, Norw 1992)Supplement* 2006; 450: 76–85.
54
55 32 De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO
56 growth reference for school-aged children and adolescents. *Bull World Health Organ* 2007; 85:
57 660–7.
58
59
60

Acknowledgement

The authors thank the mothers/caregivers and children for their participation in the study and the nurses and nurse supervisors involved in data collection.

Authors' contributions

NP, AR, DM, JS, CRS, KM contributed to the study conceptualization, and all authors contributed to the study design and data collection. NP drafted the initial manuscript and revised the paper. All authors contributed to revising the manuscript for important intellectual content and have read and approved the final manuscript.

Funding Statement

The parent trial was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Number R01 HD83113. The follow-up data collection was supported by Harvard University Center for African Studies (no grant number), the Thrasher Research Fund Early Career Award (no grant number), and the National Institutes of Health Fogarty International Center and the National Institute of Child Health & Human Development (NICHD) under Award Number D43 TW010543. NP was further supported by the Canadian Institutes for Health Research Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

Competing interests statement

The authors have no competing interests to declare.

Patient and public involvement: Patients and/or the public were not involved in the design of the study, but are involved in the conduct of and the dissemination plans of this research.

BMJ Paediatrics Open

School readiness among children born to women living with HIV in Dar es Salaam, Tanzania: a cohort study protocol

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001572.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Sep-2022
Complete List of Authors:	Perumal, Nandita; Harvard University T H Chan School of Public Health, Department of Global Health and Population Saleh, Arvin; Harvard University T H Chan School of Public Health, Department of Global Health and Population Muhihi, Alfa; Muhimbili University of Health and Allied Sciences, Department of Community Health; Management and Development for Health Seiden, Jonathan; Harvard Graduate School of Education Ndesangia, Veneranda; Muhimbili University of Health and Allied Sciences, Department of Pediatrics Ulenga, Nzovu; Management and Development for Health McCoy, Dana ; Harvard Graduate School of Education Bakari, Mohamed; Muhimbili University of Health and Allied Sciences, Department of Pediatrics Sudfeld, Christopher; Harvard University T H Chan School of Public Health, Department of Global Health and Population Manji, Karim; Muhimbili University of Health and Allied Sciences, Department of Pediatrics
Keywords:	HIV, Epidemiology, Growth

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **School readiness among children born to women living with HIV in Dar es Salaam, Tanzania: a**
4 **cohort study protocol**
5

6 Nandita Perumal¹, Arvin Saleh¹, Alfa Muhihi^{2,3}, Dana McCoy⁴, Jonathan Seiden⁴, Mohamed Bakari⁵,
7 Veneranda Ndesangia⁵, Nzovu Ulenga², Christopher R. Sudfeld^{1,6*}, Karim P. Manji^{5*}
8

9 *co-senior authors
10

11
12
13 ¹ Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston,
14 United States

15 ² Management and Development for Health, Dar es Salaam, Tanzania

16 ³ Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam,
17 Tanzania

18 ⁴ Harvard Graduate School of Education, Harvard University, Boston, United States

19 ⁵ Department of Pediatrics, Muhimbili University Health and Allied Sciences, Tanzania

20 ⁶ Department of Nutrition, Harvard TH Chan School of Public Health, Boston, United States
21
22
23

24 **Corresponding Author**

25 Nandita Perumal, PhD MPH

26 Department of Global Health and Population

27 Harvard TH Chan School of Public Health

28 90 Smith Street, 3rd Floor

29 Boston USA 02215

30 Email: nperumal@hsph.harvard.edu
31
32

33
34 Word count: 2711
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Children who are born to women living with HIV are at a greater risk of suboptimal neurodevelopment; however, evidence from sub-Saharan Africa is limited and functional developmental outcomes are rarely assessed in this vulnerable population. The School Readiness among HIV-Exposed Children (SRHEC) cohort study aims to assess the school readiness of pre-school aged children born to women living with HIV and to identify the biological, environmental, and social factors that contribute to school readiness in this population.

Methods and analysis: The SRHEC cohort is an observational follow-up study of children born to HIV-infected pregnant women who were previously enrolled in a maternal vitamin D supplementation randomized, placebo-controlled trial in Dar es Salaam, Tanzania. This parent trial enrolled 2,300 pregnant women and followed mothers and infants up to one year postpartum. Mother/caregiver and child pairs will be eligible for the SRHEC follow-up study if the child is between 3-6.5 years of age at assessment, and the mother/caregiver provides informed consent. The International Development and Early Learning Assessment (IDELA) tool will be used to assess children's school readiness, including their early literacy, early numeracy, motor, social-emotional, and executive function skills. Data on maternal and child health and nutritional status (e.g., anthropometry, blood pressure, and diet) will be collected using standardized instruments and survey-based questionnaires. Data on maternal/caregiver depression and anxiety, maternal exposure to intimate partner violence, and HIV-related stigma will also be collected. Generalized linear and logistic regressions will be used to assess the relationship between child school readiness and biological, social, environmental factors.

Ethics and Dissemination: This study received ethical clearance from the Tanzanian National Institute of Medical Research, the Muhimbili University Health and Allied Sciences, and the Harvard T.H. Chan School of Public Health. We will disseminate our results in the form of scientific conference presentations and peer-reviewed publications.

What is already known on this topic

- With increasing availability of antiretroviral therapy for HIV-infected pregnant women in low-resource settings, the number of children who are HIV-exposed but uninfected (HEU) is increasing.
- HEU children are at a greater risk of suboptimal growth and development; however, evidence to date has been primarily from high-income settings.
- Furthermore, functional developmental outcomes, such as school readiness, are rarely assessed in HIV-affected pediatric populations.

What this study hopes to add

- This prospective cohort study aims to assess the school readiness of pre-school aged children born to women living with HIV in Dar es Salaam, Tanzania.
- The study also aims to identify the biological, environmental, and social factors that contribute to school readiness in this population.
- Study findings will provide robust data for designing interventions to support school readiness and optimal growth and developmental outcomes among HIV-affected children.

Introduction

In 2015, the World Health Organization (WHO) released guidelines, known colloquially as “Option B+”, which recommended that all pregnant and breastfeeding women with human immunodeficiency virus (HIV) should initiate lifelong antiretroviral therapy (ART), regardless of HIV disease stage, to prevent mother-to-child transmission and sexual transmission of HIV, and to improve maternal clinical outcomes.¹ With global efforts continuing to increase the availability of and access to ART for women living with HIV in low-resource settings, the number of children who are HIV exposed, but uninfected (HEU) is increasing. Globally, 14.8 million children aged 0 to 14 years are estimated to be HEU, 13.2 million of whom reside in sub-Saharan Africa.² The number of HEU children has increased between 100% to ~800% in the highest burden countries in sub-Saharan Africa since 2000.³

Evidence primarily from in high-income settings suggests that children who are born to women living with HIV are at a greater risk for suboptimal cognitive, motor, behavioral, and socioemotional development as compared to their HIV-unexposed peers.⁴⁻⁶ Biological risk factors, such as exposure to HIV and ART in-utero, increased risk of maternal illness, poor nutrition during pregnancy, and increased risk of being born low birthweight or preterm have been associated with higher risk of poor development among young children.^{7,8} Numerous social, economic, and environmental factors related to living in an HIV-affected household, such as parental mental health and depression, stigma, reduced parental attention, and reduced availability of resources and income are also likely to influence children’s development.^{4,5} However, the relative contribution of the biological and social, socioeconomic and environmental risk factors on the risk of suboptimal developmental outcomes of HIV-affected children in the context of sub-Saharan Africa remains unclear. In addition, few studies have examined the functional outcomes related to early development, such as school readiness, which comprises of a range of both academic and non-academic early learning and developmental skills that support successful engagement in schools, among HIV-affected children.

1
2
3 The Sustainable Development Goal (SDG) Target 4.2 calls for all girls and boys to have access to quality
4 early childhood development, care, and pre-primary education to ensure that they are ready for primary
5 education.⁹ Given the known developmental inequities faced by young HIV-affected children, there is an
6 urgent need to understand what factors influence school readiness among HIV-affected children and to
7 develop and implement interventions to support school readiness in this vulnerable population. To this
8 end, the School Readiness among HIV-Exposed Children (SRHEC) cohort study aims to assess the
9 development and school readiness of pre-school aged children born to women living with HIV in Dar es
10 Salaam, Tanzania, and to identify the biological, social, and environmental risk and protective factors that
11 contribute to the school readiness in this population. The findings from this study will provide a unique
12 opportunity to disentangle the multi-faceted relationships that influence child school readiness in HIV-
13 affected pediatric populations, and to identify points of intervention to support child development.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Methods**

29 **Parent trial and cohort study design**

30
31 The SRHEC cohort study is a cross-sectional follow-up of children born in an individually randomized
32 double-blind, placebo-controlled trial of maternal vitamin D₃ (cholecalciferol) supplementation conducted
33 among pregnant women living with HIV in Dar es Salaam, Tanzania (ClinicalTrials.gov: NCT02305927).
34
35 The detailed protocol of the trial, which was conducted between 2015-2019, has been published
36 elsewhere.^{10,11} Briefly, the parent trial enrolled 2300 pregnant women living with HIV, who were ≥18
37 years of age, between 12 – 27 weeks gestational age, and receiving ART, to investigate whether daily
38 vitamin D supplementation (3000 IU/day) could provide a low-cost adjunct intervention to improve
39 maternal and child health outcomes. Women were enrolled in the trial from five public antenatal care
40 clinics that provided antenatal care for pregnant women living with HIV. During the trial, Tanzania used
41 the Option B+ approach, where all pregnant women living with HIV were initiated on lifelong triple-drug
42 ART, irrespective of CD4 T-cell counts or HIV disease stage. The first line of ART during the trial was
43 tenofovir/lamivudine/efavirenz, which was used by 99% of women in the trial during pregnancy and the
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 first year postpartum. Participants were followed at monthly visits during the prenatal period, at delivery,
4 at 6, 10, and 14 weeks postpartum, and monthly thereafter up to 12 months postpartum. Detailed
5 information on maternal sociodemographic characteristics, clinical outcomes (including HIV disease
6 stage), nutrition status, and depressive symptoms were collected during the prenatal period. In the
7 postpartum period, mothers' follow-up assessments included clinical examination, HIV disease stage
8 assessment, and anthropometric measurement. Child follow-up assessments included detailed clinical
9 examination, infant feeding practices, and anthropometry, as well as child development assessed by the
10 Caregiver-Reported Early Development Index¹² at the last visit. The primary outcomes of the trial were
11 maternal HIV progression or death from any cause, small-for-gestational age (SGA) births, and infant
12 stunting (length-for-age z-score <-2 standard deviation from the median of the reference population) at 12
13 months of age. Vitamin D supplementation had no effect on the primary trial outcomes.¹¹
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Participant eligibility for follow up**

29
30 All mother-child pairs who previously participated in the trial of maternal vitamin D supplementation will
31 be eligible for inclusion in the SRHEC follow-up study if: (i) child age is between 3 to 6.5 years at the
32 time of assessment, and (ii) the mother/caregiver provides informed consent. For a child whose mother
33 was enrolled in the trial of vitamin D supplementation but was not available for the follow-up study (e.g.,
34 due to death), we will ask the child's current primary caregiver for consent to participate. We will use
35 information collected during the parent trial to invite women previously enrolled in the parent trial for the
36 follow-up study. Mother/caregiver and child pairs will be invited to the study clinics to learn more about
37 the follow-up study and for study assessments if they agree to participate. Women who previously
38 withdrew from the parent trial or who were lost to follow-up during the trial period, which was until 1-
39 year postpartum, will not be contacted. Written informed consent will be obtained from all participants in
40 the local language of Kiswahili.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study procedures and assessments

Eligible mother/caregiver and child pairs who consent to participate in the follow-up study will be assessed in quiet rooms at study clinics in tertiary hospitals in Dar es Salaam, Tanzania. For each mother/caregiver and child pair we will collect detailed information on various domains, including sociodemographic factors, nutritional status, mental health status, and child development and school readiness (Table 1). Tools and procedures used to measure each of these domains are described below.

Table 1: Types of assessment planned for mother/caregiver and child pairs.

Assessment components	Mother/Caregiver*	Child
Sociodemographic characteristics	x	
Health and nutritional status	x	x
Parenting practices	x	
Mental health	x	
Social support	x	
Intimate partner violence	x	
HIV-stigma	x	
Early learning and development		
International Development and Early Learning Assessment		x
Early Child Development Index 2030		x
Strengths and Difficulties questionnaire		x

*Caregiver assessments will not include the health and nutritional status and the intimate partner violence and HIV-stigma components.

(i) Child development and school readiness: We will use the International Development and Early Learning Assessment (IDELA) tool developed by Save the Children to assess school readiness in young children aged 3 to 6.5 years in low-resource settings.¹³ Briefly, the IDELA is a tool with 22 subtasks that is easily-administered, holistic, rigorous, culturally adaptable and open-source, used to assess four core domains: (1) motor development, (2) emergent literacy, (3) emergent numeracy, (4) social-emotional development, plus an optional module on (5) executive functioning (i.e., short-term memory, inhibitory control, sustained attention). The IDELA is designed to capture broadly cross-culturally relevant skills

1
2
3 that support children's transition into formal learning environments in school. It is administered on a one-
4 on-one basis, does not require specific disciplinary trainings, and is administered using a minimal set of
5 materials: a pencil, blank paper, small items for counting (such as beans or buttons), nine picture cards,
6 and a storybook. The IDELA is scored by calculating the average percentage of correct responses for each
7 task within the four core domains (emergent numeracy, emergent literacy, motor, and social-emotional),
8 and the overall IDELA score, ranging from 0 to 100%, is calculated as the average percentage for the four
9 domain scores¹³. The IDELA tool has been previously adapted for and used in Tanzania.¹⁴ We will assess
10 inter-rater reliability for 5% of IDELA assessments selected at random.
11
12
13
14
15
16
17
18
19
20
21

22 As a secondary measure of development, we will implement the Early Child Development Index 2030
23 (ECDI2030), which is commonly used in population-based surveys to assess whether a child is meeting
24 expected developmental milestones in motor, language, math, literacy, executive functioning, and socio-
25 emotional domains.¹⁵ The ECDI2030 is used to evaluate progress towards SDG target 4.2 and is
26 administered as 20 close-ended questions to the mother or primary caregiver, where they indicate whether
27 their child has exhibited behaviors in each question. The ECDI2020 indicator is defined as the proportion
28 of children 24 to 59 months of age who have achieved the minimum number of milestones expected for
29 their age according to age-specific cut-off scores compared to all children aged 24 to 59 months of age.
30 We will also use the Strengths and Difficulties Questionnaire (SDQ), which has previously been
31 implemented in Tanzania, to assess children's overall mental health status as indexed by internalizing and
32 externalizing behaviors.¹⁶ Like the ECDI2030, the SDQ is a mother/caregiver-reported instrument; it
33 includes 25 items rated on a Likert-like scale assessing frequency of emotional problems, conduct
34 problems, hyperactivity, peer-problems and prosocial behaviour.¹⁷ The total difficulties score is generated
35 by summing the scores from all scales except the prosocial scale. All child development and school
36 readiness tools will be administered by nurses, who will be trained using the standard training procedures
37 for each tool. Although primary school in Tanzania begins at age 7 and attendance in pre-school
38 educational programs is rare in this population, we will also collect data on whether children enrolled in
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the study attended primary school and had previously or currently attended pre-school education
4
5 programs.
6
7
8

9
10 **(ii) Maternal and child health and nutrition:** We will use standardized procedures to measure
11 anthropometry. Maternal and child weight will be measured using electronic floor scale (ADE M320600,
12 Germany) with 50 g precision up to 50 kg, and 100 g precision thereafter. Participants will be requested to
13 remove shoes and wear light clothing at the time of weight measurement. Maternal and child standing
14 height will be measured using a stadiometer (ADE Mechanical Height MZ10017, Germany) with 1mm
15 precision and mid-upper arm circumference (MUAC) will be measured using a circumference tap
16 measure (ADE MZ10021, Germany) with 1mm precision. Child head circumference will be measured
17 using a Schorr tape with 1 mm precision. All child anthropometric measures will be taken in triplicate and
18 maternal measures will be recorded in duplicate. In addition to anthropometry, we will measure maternal
19 blood pressure in duplicate, using a digital blood pressure machine (OMRON BP7200) with free-size
20 cuff, with participant in a seated position after five minutes of rest. Anthropometric equipment will be
21 calibrated daily, and the blood pressure monitor will be calibrated every month using a manual mercury
22 sphygmomanometer. Minimum dietary diversity for women of reproductive age (MDD-W) will be
23 assessed using the Food and Agriculture Organization guidelines, summing the total number of different
24 food groups consumed.¹⁸ Child diet will be assessed using a modified 24-hour recall for infant and young
25 child feeding practices (removing any items relevant to children <2 years of age only) where
26 mothers/caregivers are asked about the types of foods consumed by the child in the last 24 hours to record
27 the food groups.¹⁹ We will also assess child's current health status as measured by episodes of morbidity,
28 such as diarrhea and fever, in the two-week period prior to the assessment.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **(iii) Maternal/Caregiver mental health and social support:** Maternal depression will be assessed using
53 the Hopkins Symptom Checklist (HSCL-25), which is comprised of 15 items on depressive symptoms
54
55
56
57
58
59
60

1
2
3 and 10 items on anxiousness symptoms with each item having a possible score of 1-4 (1 = not at all; to 4
4 = extremely); it has previously been validated for use in Tanzania among pregnant women living with
5 HIV.²⁰ We will also measure the mother's perception of social support using an adapted Duke University–
6 University of North Carolina Functional Social Support Questionnaire, consisting of 8 questions graded
7 on a 4-point Likert scale to measure constructs of support from confidants and affective support.²¹ The
8 tool has been previously adapted for use in Tanzania and can be used to distinguish between two
9 underlying constructs of instrumental and emotional support.²² We will also measure depression and
10 perception of social support for primary caregivers, should the mother be unavailable.
11
12
13
14
15
16
17
18
19
20
21
22

23 **(iv) Maternal HIV-related stigma and intimate partner violence (IPV):** We will measure mothers'
24 reports of HIV-related stigma using an abbreviated version the Berger scale,²³ which has been previously
25 used in Tanzania,^{24,25} and consists of 7 questions graded on a 5-point Likert scale to capture internalized
26 stigma (shame, guilt) and externalized stigma as experienced by treatment from other people who are
27 aware of the respondent's HIV status. We will also assess prevalence of IPV, which in this context is
28 most commonly directed towards women by male partners. IPV has been described to manifest in a range
29 of behaviors, including but not limited to: physical, sexual, emotional or psychological, and controlling
30 behaviors that include restricting financial or economic independence.²⁶ Physical and sexual aspects of
31 IPV will be assessed using an abbreviated mother-reported IPV module found in the Tanzania
32 Demographic and Health Survey and has been previously used in other studies.^{27,28} Emotional and
33 economic aspects of IPV will be assessed using abbreviated questions that were previously used in
34 Tanzania.²⁹ We will not assess HIV-related stigma or IPV for caregivers.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **(v) Caregiving practices and resources for learning:** Caregiving practices, including disciplinary
52 practices, such as corporal punishment, and responsive caregiving and stimulation practices (e.g., reading,
53 counting, playing), will be measured using the mother/caregiver-reported Family Care Indicators (FCI)
54
55
56
57
58
59
60

1
2
3 taken from the Multiple Indicator Cluster Surveys.^{30,31} The FCI score will be a summative score based on
4 responses (yes/no) for each individual item. We will also collect data on resources available for learning,
5 such as books and toys, to assess children's learning environment at home.
6
7
8
9

10
11 **(vi) Maternal HIV variables at time of assessment:** We will seek consent to retrieve mother's medical
12 information from the HIV treatment clinic and to link HIV treatment information, including information
13 on HIV disease stage based on the WHO classification, history of ART regimens, viral load and
14 laboratory results.
15
16
17
18
19

20
21 **(vii) Data collected during pregnancy and first year postpartum:** We will link the maternal/caregiver
22 and child data collected in this study with existing data from parent vitamin D supplementation trial to
23 assess long-term associations of maternal and child perinatal health with child development and school
24 readiness in the pre-school years.
25
26
27
28
29

30 31 32 **Safety procedures and referrals**

33
34 All research staff will be trained in a 2-week training workshop where they will learn about and
35 familiarize themselves with all study procedures, including the planned referral scheme and supports that
36 will be made available to participants and their children. Study staff members will also be trained in
37 referring study mothers/caregivers for mental health care if they report IPV or depression. If signs of
38 suicidality are reported, mothers/caregivers will be kept under observation until they are seen by a clinical
39 psychiatrist and referred for mental health services. Mothers/caregivers and their children will be referred
40 to clinical and nutritional services at the hospital if undernutrition and malnutrition are detected. We will
41 follow strict safety precautions and procedures (e.g., masks, hand sanitizers) to prevent the transmission
42 of COVID-19 among the study staff and participants.
43
44
45
46
47
48
49
50
51
52
53

54 55 **Sample size**

1
2
3 All mother and infant pairs who were discharged from the parent trial at 12 months postpartum (n = 2053)
4 will be eligible for the SRHEC follow-up study and will be invited to participate in the study.
5
6
7
8

9 **Quality assurance and data management**

10 Standardization sessions will be held every 3 months to ensure the data collectors are following the
11 recommended techniques, to monitor reliability (precision and accuracy), and to take corrective measures
12 if required. Data queries will be regularly generated and checked by study field staff as part of quality
13 assurance/quality control measures to detect outliers and possible erroneous values.
14
15
16
17
18
19
20
21

22 **Statistical analysis**

23 We will generate summary statistics, overall and by age-strata, of child outcome domains as described in
24 the standard methodology for the IDELA, ECDI2030, and SDQ measures including both domain-level
25 and overall scores where appropriate. Subscale scores for caregiving practices, resources for learning,
26 maternal depression, and anxiety, will be similarly derived using internationally validated standards and
27 cutoffs when available, and summative scores or z-scores as relevant. Child growth will be assessed using
28 standardized indices and indicators of anthropometric measures using the World Health Organization
29 Child Growth Standards.^{32,33} Scores for child development and school readiness will be converted to
30 overall z-scores based on study sample distribution with a mean of 0 and an SD of 1 for analysis. Using
31 these standardized scores, we will assess the relationship between early child development assessed in the
32 parent trial, at approximately 12 months of age, and school readiness. We will also estimate differences in
33 child health, nutrition, development and school readiness outcome scores across different exposures of
34 interest using generalized linear regression models. Child age will be included as a confounder or effect
35 modifier in all regression analysis, as appropriate. Relationships with categorial indicators of suboptimal
36 child development will be estimated using modified Poisson regression with robust standard errors. All
37 regression models will be adjusted for potential sociodemographic confounders, such as child age, child
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sex, maternal/caregiver age, household wealth quintile, and number of children in the household, among
4
5 others.
6
7
8

9 **Ethics and dissemination**

10 This study received ethical clearance from the Tanzanian National Institute of Medical Research, the
11 Muhimbili University Health and Allied Sciences, and the Harvard TH Chan School of Public Health.
12
13 Permission to conduct the study was granted by the President's Office, Regional Administration and
14
15 Local Government (PORALG) and the Regional Medical Officer (RMO) of Dar-es-Salaam. We will
16
17 disseminate our results in the form of scientific conference presentations, presentations to the RMO, and
18
19 as peer-reviewed publications.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 World Health Organization. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. *Geneva WHO* 2012; : 1–117.
- 2 Slogrove A, Reikie B, Naidoo S, *et al.* HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. *J Trop Pediatr* 2012; **58**: 505–8.
- 3 Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global population of children who are HIV-exposed and uninfected, 2000–18: a modelling study. *Lancet Glob Heal* 2020; **8**: e67–75.
- 4 Sherr L, Croome N, Parra Castaneda K, Bradshaw K, Herrero Romero R. Developmental challenges in HIV infected children-An updated systematic review. *Child Youth Serv Rev* 2014; **45**: 74–89.
- 5 Le Doaré K, Bland R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. *Pediatrics* 2012; **130**. DOI:10.1542/peds.2012-0405.
- 6 Stein A, Desmond C, Garbarino J, *et al.* Predicting long-term outcomes for children affected by HIV and AIDS: Perspectives from the scientific study of children’s development. *Aids* 2014; **28**: 261–8.
- 7 Chen JY, Ribaud HJ, Souda S, *et al.* Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in botswana. *J Infect Dis* 2012; **206**: 1695–705.
- 8 Moran NF, Moodley J. The effect of HIV infection on maternal health and mortality. *Int J Gynecol Obstet* 2012; **119**: 26–9.
- 9 UNICEF. The sustainable development goals. 2015.
- 10 Sudfeld CR, Manji KP, Duggan CP, *et al.* Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: Study protocol for a randomized controlled trial. *Trials* 2017; **18**: 1–12.
- 11 Sudfeld CR, Manji KP, Muhihi A, *et al.* Vitamin D3 supplementation during pregnancy and lactation for women living with HIV in Tanzania: A randomized controlled trial. *PLoS Med* 2022; **19**: e1003973.
- 12 McCoy DC, Sudfeld CR, Bellinger DC, *et al.* Development and validation of an early childhood development scale for use in low-resourced settings. *Popul Health Metr* 2017; **15**: 1–18.
- 13 Pisani L, Borisova I, Dowd AJ. Developing and validating the International Development and Early Learning Assessment (IDELA). *Int J Educ Res* 2018; **91**: 1–15.
- 14 EQUIP-T. Review of the EQUIP-Tanzania School Readiness Programme. 2016; : 1–36.
- 15 Cappa C, Petrowski N, De Castro EF, *et al.* Identifying and minimizing errors in the measurement of early childhood development: Lessons learned from the cognitive testing of the ECDI2030. *Int J Environ Res Public Health* 2021; **18**. DOI:10.3390/ijerph182212181.
- 16 Winje BA, Kvestad I, Krishnamachari S, *et al.* Does early vitamin B₁₂ supplementation improve neurodevelopment and cognitive function in childhood and into school age: a study protocol for extended follow-ups from randomised controlled trials in India and Tanzania. *BMJ Open* 2018; **8**: e018962.
- 17 Hoosen N, Davids EL, de Vries PJ, Shung-King M. Correction: The Strengths and Difficulties

- Questionnaire (SDQ) in Africa: A scoping review of its application and validation [Child Adolesc Psychiatry Ment Health., 12, (2018) (6)] DOI: 10.1186/s1303401702121. *Child Adolesc Psychiatry Ment Health* 2018; **12**: 1–39.
- 18 FAO & FHI 360. Minimum Dietary Diversity for Women- A Guide to Measurement. 2016 www.fao.org/publications%0Ahttps://www.sciencedirect.com/science/article/abs/pii/S0306919217301902.
- 19 WHO and UNICEF. Indicators for assessing infant and young child feeding practices. *World Heal Organ United Nations Child Fund* 2021; **WHA55 A55/**: 19.
- 20 Kaaya SF, Fawzi MCS, Mbwambo JK, Lee B, Msamanga GI, Fawzi W. Validity of the Hopkins Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania. *Acta Psychiatr Scand* 2002; **106**: 9–19.
- 21 Broadhead_The Duke-UNC Functional Social Support Questionnaire.pdf. .
- 22 Regan M, Muhihi A, Nagu T, *et al*. Depression and Viral Suppression Among Adults Living with HIV in Tanzania. *AIDS Behav* 2021; **25**: 3097–105.
- 23 Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. *Res Nurs Heal* 2001; **24**: 518–29.
- 24 Smith Fawzi MC, Siril H, Larson E, *et al*. Healthy Options: Study protocol and baseline characteristics for a cluster randomized controlled trial of group psychotherapy for perinatal women living with HIV and depression in Tanzania. *BMC Public Health* 2020; **20**: 1–10.
- 25 Fawzi MCS, Siril H, Liu Y, *et al*. Agents of change among people living with HIV and their social networks: Stepped-wedge randomised controlled trial of the NAMWEZA intervention in Dar es Salaam, Tanzania. *BMJ Glob Heal* 2019; **4**: 1–14.
- 26 Krishnan N, Bewsley S. Domestic abuse. In: Dalton M, ed. *Forensic Gynaecology (Royal College of Obstetricians and Gynaecologists Advanced Skills)*. Cambridge: Cambridge University Press, 2014: 148–62.
- 27 Neamah HH, Sudfeld C, McCoy DC, *et al*. Intimate partner violence, depression, and child growth and development. *Pediatrics* 2018; **142**. DOI:10.1542/peds.2017-3457.
- 28 TDHS. Tanzania 2015-16 Demographic Health Survey and Malaria Indicator Survey. *Tanzania 2015-16 Demogr Heal Surv Malar Indic Surv* 2016; : 24.
- 29 Harvey S, Lees S, Mshana G, *et al*. A cluster randomized controlled trial to assess the impact on intimate partner violence of a 10-session participatory gender training curriculum delivered to women taking part in a group-based microfinance loan scheme in Tanzania (MAISHA CRT01): Study pro. *BMC Womens Health* 2018; **18**: 1–12.
- 30 Hamadani JD, Tofail F, Hilaly A, Huda SN, Engle P, Grantham-McGregor SM. Use of family care indicators and their relationship with child development in Bangladesh. *J Heal Popul Nutr* 2010; **28**: 23–33.
- 31 Kariger P, Frongillo EA, Engle P, Britto PMR, Sywulka SM, Menon P. Indicators of family care for development for use in multicountry surveys. *J Heal Popul Nutr* 2012; **30**: 472–86.
- 32 WHO Multicentre Growth Reference SG. WHO Child Growth Standards based on Legnth/height, weight and age. *Acta Paediatr (Oslo, Norw 1992)Supplement* 2006; **450**: 76–85.
- 33 De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

growth reference for school-aged children and adolescents. *Bull World Health Organ* 2007; **85**: 660–7.

Confidential: For Review Only

Acknowledgement

The authors thank the mothers/caregivers and children for their participation in the study and the nurses and nurse supervisors involved in data collection.

Authors' contributions

NP, AS, DM, JS, CRS, KM contributed to the study conceptualization, and all authors contributed to the study design and data collection. NP drafted the initial manuscript and revised the paper. All authors contributed to revising the manuscript for important intellectual content and have read and approved the final manuscript.

Funding Statement

The parent trial was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Number R01 HD83113. The follow-up data collection was supported by Harvard University Center for African Studies (no grant number), the Thrasher Research Fund Early Career Award (no grant number), and the National Institutes of Health Fogarty International Center and the National Institute of Child Health & Human Development (NICHD) under Award Number D43 TW010543. NP was further supported by the Canadian Institutes for Health Research Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

Competing interests statement

The authors have no competing interests to declare.

Patient and public involvement: Patients and/or the public were not involved in the design of the study, but are involved in the conduct of and the dissemination plans of this research.